Rhythm Biosciences LimitedASX: RHY

Market Update - All End of CY24 Milestones Attained

· Issued by Rhythm Biosciences Limited

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The company is progressing towards the commercial launch of its next-generation colorectal cancer diagnostic, with plans for further testing and clinical validation. Additionally, Rhythm has engaged consultants to assist with regulatory pathways in key markets, aiming for a commercial rollout in the second half of the calendar year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Rhythm Biosciences Limited on 6ix

Earlier from Rhythm Biosciences

Later from Rhythm Biosciences

All Rhythm Biosciences news releases